Eventum Orthopaedics: Pioneering a New Era in Knee Surgery
March 19, 2025, 3:31 am
Location: United Kingdom, England
Employees: 1-10
Founded date: 2020
Total raised: $9.94M
In the world of medical technology, innovation is the lifeblood that keeps the industry thriving. Eventum Orthopaedics, a company based in Ilkley, UK, is making waves in the field of knee replacement surgery. With a recent funding boost of €4.5 million, the company is set to enhance its flagship product, the QuadSense device, and expand its reach across international markets. This funding round, led by Mercia Ventures and the Northern Powerhouse Investment Fund (NPIF), brings the total investment in Eventum to over €8.3 million.
Founded in 2020 by seasoned medical executives John Naybour and Paul Atherton, Eventum aims to tackle a pressing issue in knee surgeries. Every year, over 2 million patients undergo knee replacements globally. Yet, a staggering 20% of these patients are dissatisfied with the results. This statistic is a wake-up call. It highlights a gap in the current surgical practices that Eventum is determined to bridge.
The QuadSense device is a game-changer. It provides surgeons with real-time data on the position of the kneecap during surgery. This precision is crucial. The kneecap's placement can significantly impact the knee's function post-surgery. By improving this aspect, Eventum aims to boost patient satisfaction and reduce the number of unhappy patients.
The device has already gained regulatory approvals in the UK and the US, a testament to its credibility and potential. With over 300 procedures already performed using QuadSense, the feedback from the orthopaedic community has been overwhelmingly positive. Surgeons are eager to adopt this technology, recognizing its potential to enhance surgical outcomes.
The financial backing from NPIF and Mercia Ventures is not just a vote of confidence; it’s a lifeline. This funding will allow Eventum to build up its product stocks following its launch in key markets, including the UK, US, and New Zealand. Additionally, the company is set to develop two new devices aimed at shoulder and hip operations. This diversification could position Eventum as a leader in the MedTech space, not just for knees but for other critical joints as well.
The implications of Eventum's success extend beyond the operating room. The cost of treating dissatisfied patients can range from £5,000 to £6,000 per case. By improving surgical outcomes, Eventum could save the healthcare system significant amounts of money. This financial incentive is crucial for hospitals and clinics that are often stretched thin.
The Northern Powerhouse Investment Fund II (NPIF II) plays a vital role in supporting businesses like Eventum. With a focus on fostering growth in the North of England, NPIF II provides loans and equity investments to small and medium-sized enterprises (SMEs). This initiative not only fuels innovation but also creates jobs and stimulates the regional economy. Eventum is a shining example of how local businesses can harness this support to expand and thrive.
As Eventum gears up for international expansion, the company is also focused on building a robust distribution network. Appointing distributors in key markets is essential for ensuring that the QuadSense device reaches the surgeons who need it most. This strategic move will help the company scale its operations and increase its market presence.
The journey of Eventum Orthopaedics is just beginning. With a dedicated team of ten, the company is poised for growth. The leadership of Naybour and Atherton, combined with the innovative spirit of their product, sets a strong foundation for future success.
In a world where patient satisfaction is paramount, Eventum’s mission resonates deeply. The company is not just selling a product; it’s offering hope. Hope for better surgical outcomes. Hope for improved quality of life.
As the healthcare landscape continues to evolve, companies like Eventum are at the forefront of change. They are not merely participants in the industry; they are pioneers. Their work is a reminder that with the right tools and data, we can transform the way surgeries are performed and, ultimately, the lives of patients.
In conclusion, Eventum Orthopaedics is more than a MedTech company. It is a beacon of innovation in knee surgery. With its QuadSense device, the company is on a mission to redefine success in total knee replacements. As it continues to grow and expand, the impact of its work will be felt far and wide. The future of knee surgery looks brighter, thanks to Eventum.
Founded in 2020 by seasoned medical executives John Naybour and Paul Atherton, Eventum aims to tackle a pressing issue in knee surgeries. Every year, over 2 million patients undergo knee replacements globally. Yet, a staggering 20% of these patients are dissatisfied with the results. This statistic is a wake-up call. It highlights a gap in the current surgical practices that Eventum is determined to bridge.
The QuadSense device is a game-changer. It provides surgeons with real-time data on the position of the kneecap during surgery. This precision is crucial. The kneecap's placement can significantly impact the knee's function post-surgery. By improving this aspect, Eventum aims to boost patient satisfaction and reduce the number of unhappy patients.
The device has already gained regulatory approvals in the UK and the US, a testament to its credibility and potential. With over 300 procedures already performed using QuadSense, the feedback from the orthopaedic community has been overwhelmingly positive. Surgeons are eager to adopt this technology, recognizing its potential to enhance surgical outcomes.
The financial backing from NPIF and Mercia Ventures is not just a vote of confidence; it’s a lifeline. This funding will allow Eventum to build up its product stocks following its launch in key markets, including the UK, US, and New Zealand. Additionally, the company is set to develop two new devices aimed at shoulder and hip operations. This diversification could position Eventum as a leader in the MedTech space, not just for knees but for other critical joints as well.
The implications of Eventum's success extend beyond the operating room. The cost of treating dissatisfied patients can range from £5,000 to £6,000 per case. By improving surgical outcomes, Eventum could save the healthcare system significant amounts of money. This financial incentive is crucial for hospitals and clinics that are often stretched thin.
The Northern Powerhouse Investment Fund II (NPIF II) plays a vital role in supporting businesses like Eventum. With a focus on fostering growth in the North of England, NPIF II provides loans and equity investments to small and medium-sized enterprises (SMEs). This initiative not only fuels innovation but also creates jobs and stimulates the regional economy. Eventum is a shining example of how local businesses can harness this support to expand and thrive.
As Eventum gears up for international expansion, the company is also focused on building a robust distribution network. Appointing distributors in key markets is essential for ensuring that the QuadSense device reaches the surgeons who need it most. This strategic move will help the company scale its operations and increase its market presence.
The journey of Eventum Orthopaedics is just beginning. With a dedicated team of ten, the company is poised for growth. The leadership of Naybour and Atherton, combined with the innovative spirit of their product, sets a strong foundation for future success.
In a world where patient satisfaction is paramount, Eventum’s mission resonates deeply. The company is not just selling a product; it’s offering hope. Hope for better surgical outcomes. Hope for improved quality of life.
As the healthcare landscape continues to evolve, companies like Eventum are at the forefront of change. They are not merely participants in the industry; they are pioneers. Their work is a reminder that with the right tools and data, we can transform the way surgeries are performed and, ultimately, the lives of patients.
In conclusion, Eventum Orthopaedics is more than a MedTech company. It is a beacon of innovation in knee surgery. With its QuadSense device, the company is on a mission to redefine success in total knee replacements. As it continues to grow and expand, the impact of its work will be felt far and wide. The future of knee surgery looks brighter, thanks to Eventum.